>There's always a little danger in talking with people in a business who may not have the whole picture but it's good info nonetheless.
There are always slight difference is accounting treatment - but management KPI's even more so.
>I think in a consultancy environment there shouldn't be non-chargeable staff.
Agree - though I am told this view is "old fashioned".
> It's a good point though - 85% cost based utilisation is unrealistic - more of an ideal situation to try for.
I don't think 75% or 80% cost based utilisation is unrealistic - the larger and more beuracratic a business becomes the worse the utilisation I suppose.
Many clients have spoken openly about the high projects costs in Australia. Larger resources projects in particular had large bureaucracies attached to them. This overhead is a hard sell in the current market as the project mix adjusts.
Agree all insights are useful.
The timing of the dip towards 55% in the utilisation trend coincides with holiday closure. The step up is positive.
- Forums
- ASX - By Stock
- Ann: Final Director's Interest Notice - R Wankmuller-CDD.AX
>There's always a little danger in talking with people in a...
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CDD (ASX) to my watchlist
(20min delay)
|
|||||
Last
31.5¢ |
Change
-0.005(1.56%) |
Mkt cap ! $12.30M |
Open | High | Low | Value | Volume |
31.0¢ | 32.0¢ | 30.0¢ | $9.778K | 31.31K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 20221 | 31.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
32.0¢ | 62309 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 20221 | 0.310 |
7 | 80656 | 0.300 |
1 | 115 | 0.295 |
1 | 3570 | 0.280 |
1 | 400 | 0.250 |
Price($) | Vol. | No. |
---|---|---|
0.320 | 62309 | 4 |
0.330 | 20000 | 1 |
0.340 | 20000 | 1 |
0.350 | 6075 | 1 |
0.370 | 30000 | 1 |
Last trade - 15.31pm 10/10/2024 (20 minute delay) ? |
Featured News
CDD (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham, MD & CEO
James Graham
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online